Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Investors in Becton Dickinson and Company BDX, popularly known as BD, need to pay close attention to the stock based on moves in the options market lately. That is because the March 21, 2025 $120.00 ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

According to the company, medical essentials and interventional lead the medical technology unit's business lines, bringing ...

A new BD will have four new operating segments: medical essentials, connected care, BioPharma systems and interventional.

CEO Tom Polen said BD will “double down on shifting our portfolio, both organically and inorganically through tuck-in M&A, into higher-growth, high-margin accretive growth spaces.” ...

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

Becton, Dickinson and Company (BD) announced plans to separate its Biosciences and Diagnostic Solutions business into ...

Saudi German Health (SGH), one of the leading healthcare providers in the region, signed a Memorandum of Understanding (MoU) ...

Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and ...

Consensus is $14.35. Sees FY25 revenue $21.7B-$21.9B vs. previous view $21.9B-$22.1B, consensus $21.93B.Maximize Your Portfolio with Data ...

BD announced it would split from its biosciences and diagnostics unit, while Zimmer Biomet updated investors on its $1.1 ...